Goldman Sachs Sees Clear Recovery in China's CRO/CDMO Sector, Favorable on WuXi-Linked Stocks

Stock News09:50

Goldman Sachs has released a research report indicating that the second quarter and first-half results this year reflect a clear recovery in China's CRO/CDMO industry, with companies exceeding earnings expectations, raising guidance, and reporting robust order books. The bank has assigned "Buy" ratings to Wuxi AppTec (02359), WuXi XDC (02268), Asymchem (06821), and Pharmaron (03759).

Goldman Sachs has set target prices of HK$220.1 for Wuxi AppTec, HK$97.9 for WuXi XDC, HK$37.2 for Pharmaron, HK$168.2 for Asymchem, HK$52.1 for Tigermed (03347), and HK$38.54 for GenScript (01548).

The investment bank noted that biotech companies turned profitable in the first half of the year, with business development revenue and operational leverage also receiving support, attracting investor attention. Additionally, market concerns over anti-corruption measures have eased.

Within the sector, Goldman Sachs prefers Innovent Biologics (01801), Kelun-Biotech (06990), KeyMed Biosciences (02162), GenFleet Therapeutics (02595), and Hansoh Pharmaceutical (03692), all rated "Buy." The target prices are HK$120.6, HK$581.2, HK$118.88, HK$52, and HK$52.7, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment